Form 4: Adaptive Biotechnologies Director Acquires Shares and Options

Robert Hershberg, a director at Adaptive Biotechnologies, acquired shares and stock options on March 4, 2024, according to a recent SEC filing.

Summary

• On March 4, 2024, Robert Hershberg, a director of Adaptive Biotechnologies Corp, acquired 31,328 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Hershberg directly owns 107,296 shares.
• Hershberg also acquired options to purchase 48,044 shares of common stock at an exercise price of $3.99.
• The options vest in equal monthly installments over one year from March 4, 2024, contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, and their potential sentiment towards the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates